Wuxi PharmaTech New Drug Development Co., Ltd. was established on June 5438+February, 2000. It is the world's leading pharmaceutical, biotechnology and medical device R&D outsourcing service company, with operating entities in China and the United States. On August 9, 2007, the parent company Wuxi Wuxi Wuxi Wuxi PharmaTech (Cayman) Co., Ltd. was officially listed on the New York Stock Exchange, and its American Depositary Receipts trading code was WX. As a research-oriented and customer-centered company, Wuxi PharmaTech provides a series of comprehensive laboratory research and development, research and production, biological agent testing and production services for pharmaceutical companies, biotechnology companies and medical device companies around the world, and the service scope runs through the whole process of pharmaceutical and medical device research and development. WuXi PharmaTech's service aims to help its global partners shorten the research and development cycle of drugs and medical devices and reduce the research and development costs. Our services are divided into two parts: laboratory services, including synthetic chemistry, biological detection, toxicology, preclinical drug development, analytical services, biopharmaceuticals and medical device testing, and other related contract research and development services. Production services, pharmaceutical intermediates, API production services, cell bank services, cell therapy and cGMP products based on compounds and tissues. The company's top management team consists of a group of doctors and MBA students with rich experience in the fields of pharmacy, biotechnology and medical device research and development. Our senior management team * * * has more than 200 authorized and pending patent achievements, more than 800 high-level academic papers, and an average of 15 years of working experience in international first-class pharmaceutical, biopharmaceutical and medical device companies. The total number of employees in the company has exceeded 3700. The company's facilities in China include 59,000 square meters of R&D center in Shanghai Waigaoqiao Free Trade Zone, 20,400 square meters of R&D and cGMP production bases in Jinshan District of Shanghai, 33,000 square meters of second-phase expansion project, 65,438+02,000 square meters of R&D center in Tianjin, which mainly provides chemical services for drug research and development, and 30,000 square meters. The company's facilities in the United States have all been approved by the US Food and Drug Administration, including the 7700-square-meter R&D and production center in St. Paul, Minnesota, the 4600-square-meter testing center in Atlanta, Georgia, and the 7000-square-meter R&D testing and production center in Philadelphia, Pennsylvania. Interested parties please log on to the company website /hrtest/Default2.aspx to fill in your resume. Company website: Address: No.288, Ford Middle Road, Waigaoqiao Free Trade Zone, Shanghai Postal Code: 200 13 1 Contact :hr@wuxiapptec.com E-mail :hr@wuxiapptec.com.